Inventors: Peter D. Burbelo and Michael J. Iadarola (NIDCR).

Related Publications:

PATENT:

Application:
Licensed: Available for licensing.

Licensing Contact: Norbert Pontzer, J.D., Ph.D. at 301–435–5502; pontzer@mail.nih.gov.

Collaborative Research Opportunity: The National Institute of Dental and Craniofacial Research, Laboratory of Sensory Biology, Neurobiology and Pain Therapeutics Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact David W. Bradley, Ph.D. at 301–402–0540 or bradley@nih.gov for more information.


Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2010–1668 Filed 1–27–10; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

Nitric Oxide-Based Therapeutics for Lung Cancer

Description of Invention: JS–36–25, a diazeniumdiolate prodrug, is available for licensing and development of treatments for lung cancer. The inventors have demonstrated a potent tumoristatic activity of JS–36–25 in both lung cancer cells in vitro and as xenografts in mice. JS–36–25 treatment led to 85% reduction of tumor growth in vivo. The tumoristatic potency of the compound correlated well with the level of endogenous reactive oxygen species (ROS) in the cancer cells. Thus, in addition to potent tumoristatic activity when administered alone, this compound is predicted to have a strong synergy with therapeutics that act through generation of ROS, such as bortezomib, doxorubicin, as well as high-energy radiation.

Applications: Development of lung cancer treatments.

Development Status: Pre-clinical.

Market: There are over 160,000 new cases of lung cancer every year in the United States alone.

Inventors: Anna E. Maciag et al. (NCI).


Licensing Status: Available for licensing.

Licensing Contact: Steve Standley, Ph.D.; 301–435–4074; sstand@od.nih.gov.

T-Cell-Specific Gfi-1 Knockout Mouse

Description of Invention: This is a mouse model available to study T-cell differentiation. Growth factor independent 1 (GFI-1) is a transcriptional repressor that is transiently induced during T-cell activation. Th17-inducible lineage is a GFI-1[lox/lox] introduced into a mouse Cre controlled by a CD4 promoter, which allows selective removal of GFI-1 exclusively in T-cells. It has thus far been used to demonstrate that GFI-1 plays a critical role in enhancing Th2 cell expansion and repressing induction of Th17 and CD103+ ITR cells.

Applications: Tool for studying T-cell proliferation and differentiation.

Inventors: Jinfeng Zhu and William E. Paul (NIAID).


Licensing Status: This technology is available as a research tool under a Biological Materials License.

Licensing Contact: Steve Standley, Ph.D.; 301–435–4074; sstand@od.nih.gov.


Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2010–1668 Filed 1–27–10; 8:45 am]

BILLING CODE 4140–01–P